We are international

57th Annual Meeting of the American Society of Hematologists (ASH)
December 3-7, 2015
Orlando, FL

ASH 2015: Dr. Paul Richardson's ASH Overview

Dr. Paul Richardson
Dana-Farber Cancer Institute
Boston, MA

Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

Dr. Michel Attal
Institut Universitaire du Cancer de Toulouse-Oncopole
Toulouse, France

The IMWG Conference Series "Making Sense of Treatment"
57th ASH Annual Meeting | Dec. 7, 2015

Drs. Brian GM Durie, Joseph Mikhael, Antonio Palumbo, and Paul Richardson discusses the latest news and trends in the treatment of Multiple Myeloma.

  • MRD Testing:  Is it Ready for Primetime?
  • Frontline Therapy:  What are the Best Option in 2015/2016
  • Relapse: How Do You Prioritize New Choices?
  • New Agents: Which Are Best and How Do We Assess? 
Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma

Dr. Saad Usmani
Levine Cancer Institute
Charlotte, NC

Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up

Dr. Meletios Dimopoulos
National and Kapodistrian University of Athens
School of Medicine
Athens, Greece

Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

Dr. Ashutosh Wechalekar
National Amyloidosis Centre
University College London
London, United Kingdom

ASH 2015: Dr. Saad Usmani ASH Overview

Dr. Saad Usmani
Levine Cancer Institute
Carolinas Healthcare System
Charlotte, NC

ASH 2015: Dr. Sagar Lonial ASH Overview

Dr. Sagar Lonial
Emory University
Atlanta, GA

ASH 2015: Dr. Morie Gertz ASH Overview

Dr. Morie Gertz
Mayo Clinic
Rochester, MN

ASH 2015: Dr. Kenneth Anderson ASH Overview

Dr. Kenneth Anderson
Dana-Farber Cancer Institute
Boston, MA

Global Advances in Myeloma:
Providing Best Options for Treatment in 2015

Join us for a provocative program format that includes “point and counterpoint” presentations and interactive case discussions to provide varied perspectives on new data, guideline changes, and expert recommendations in multiple myeloma.

Interact with international experts as they debate clinical questions and discuss how these challenges affect therapeutic decisions faced by clinicians treating myeloma. 

Friday Satellite Symposium preceding the 57th ASH Annual Meeting.